{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:49:04Z","timestamp":1793155744616,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-026-01157-8","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:02:07Z","timestamp":1777626127000},"page":"840-856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-8222","authenticated-orcid":false,"given":"Bernhard","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Rusterholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Epp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5810-1395","authenticated-orcid":false,"given":"Michael","family":"Hettich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Kazantzidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"Rieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6004-8095","authenticated-orcid":false,"given":"Petra C.","family":"Schwalie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solveig","family":"Badillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9081-7237","authenticated-orcid":false,"given":"Nadine","family":"Kumpesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3998-7968","authenticated-orcid":false,"given":"Andreas","family":"Thommen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle J.","family":"Vugts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6099-4236","authenticated-orcid":false,"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Lostes Bardaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Castanon","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"de Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iben","family":"Spanggaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9749-4638","authenticated-orcid":false,"given":"Dae Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3732-8491","authenticated-orcid":false,"given":"James","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4832-7008","authenticated-orcid":false,"given":"Fiona","family":"Thistlethwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivera","family":"Cirovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9314","authenticated-orcid":false,"given":"Stefan N.","family":"Symeonides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"1157_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","volume":"229","author":"R Elgueta","year":"2009","unstructured":"Elgueta, R. et al. Molecular mechanism and function of CD40\/CD40L engagement in the immune system. Immunol. Rev. 229, 152\u2013172 (2009).","journal-title":"Immunol. Rev."},{"key":"1157_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/8426","volume":"5","author":"RR French","year":"1999","unstructured":"French, R. R., Chan, H. T., Tutt, A. L. & Glennie, M. J. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5, 548\u2013553 (1999).","journal-title":"Nat. Med."},{"key":"1157_CR3","doi-asserted-by":"crossref","unstructured":"Vonderheide, R. H. CD40 agonist antibodies in cancer immunotherapy. Annu. Rev. Med. 71, 47\u201358 (2020).","DOI":"10.1146\/annurev-med-062518-045435"},{"key":"1157_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","volume":"25","author":"RH Vonderheide","year":"2007","unstructured":"Vonderheide, R. H. et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25, 876\u2013883 (2007).","journal-title":"J. Clin. Oncol."},{"key":"1157_CR5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.4161\/cbt.10.10.13251","volume":"10","author":"J R\u00fcter","year":"2010","unstructured":"R\u00fcter, J., Antonia, S. J., Burris, H. A., Huhn, R. D. & Vonderheide, R. H. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol. Ther. 10, 983\u2013993 (2010).","journal-title":"Cancer Biol. Ther."},{"key":"1157_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3109\/10428190903440946","volume":"51","author":"RR Furman","year":"2010","unstructured":"Furman, R. R., Forero-Torres, A., Shustov, A. & Drachman, J. G. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk. Lymphoma 51, 228\u2013235 (2010).","journal-title":"Leuk. Lymphoma"},{"key":"1157_CR7","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1158\/1078-0432.CCR-14-2355","volume":"21","author":"P Johnson","year":"2015","unstructured":"Johnson, P. et al. Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study. Clin. Cancer Res. 21, 1321\u20131328 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1157_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10637-022-01319-2","volume":"41","author":"V Moreno","year":"2023","unstructured":"Moreno, V. et al. A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors. Invest. New Drugs 41, 93\u2013104 (2023).","journal-title":"Invest. New Drugs"},{"key":"1157_CR9","doi-asserted-by":"publisher","unstructured":"Coveler, A. L. et al. Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2022-005584 (2023).","DOI":"10.1136\/jitc-2022-005584"},{"key":"1157_CR10","doi-asserted-by":"publisher","first-page":"e1468956","DOI":"10.1080\/2162402X.2018.1468956","volume":"7","author":"DL Bajor","year":"2018","unstructured":"Bajor, D. L. et al. Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. Oncoimmunology 7, e1468956 (2018).","journal-title":"Oncoimmunology"},{"key":"1157_CR11","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/1750743X.2024.2359359","volume":"16","author":"B Tran","year":"2024","unstructured":"Tran, B. et al. A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors. Immunotherapy 16, 759\u2013774 (2024).","journal-title":"Immunotherapy"},{"key":"1157_CR12","doi-asserted-by":"publisher","first-page":"e23033","DOI":"10.4161\/onci.23033","volume":"2","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide, R. H. et al. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2, e23033 (2013).","journal-title":"Oncoimmunology"},{"key":"1157_CR13","doi-asserted-by":"publisher","unstructured":"Dziadek, S. et al. Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1352615 (2024).","DOI":"10.3389\/fimmu.2024.1352615"},{"key":"1157_CR14","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1073\/pnas.91.12.5657","volume":"91","author":"MJ Scanlan","year":"1994","unstructured":"Scanlan, M. J. et al. Molecular cloning of fibroblast activation protein a, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl Acad. Sci. USA 91, 5657\u20135661 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1157_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abp9229","volume":"15","author":"I Melero","year":"2023","unstructured":"Melero, I. et al. A first-in-human study of the fibroblast activation protein\u2013targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Sci. Transl. Med. 15, eabp9229 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1157_CR16","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1158\/1078-0432.CCR-23-3567","volume":"30","author":"N Steeghs","year":"2024","unstructured":"Steeghs, N. et al. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity from a phase I study of simlukafusp alfa (FAP-IL2v) in advanced\/metastatic solid tumors. Clin. Cancer Res. 30, 2693\u20132701 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1157_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bbrc.2017.03.039","volume":"487","author":"L Chen","year":"2017","unstructured":"Chen, L. et al. FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression. Biochem. Biophys. Res. Comm. 487, 8\u201314 (2017).","journal-title":"Biochem. Biophys. Res. Comm."},{"key":"1157_CR18","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.3390\/cancers12113238","volume":"12","author":"M Herrera","year":"2020","unstructured":"Herrera, M. et al. Prognostic interactions between FAP+ fibroblasts and CD8a+ T cells in colon cancer. Cancers 12, 3238 (2020).","journal-title":"Cancers"},{"key":"1157_CR19","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1158\/1078-0432.CCR-20-4001","volume":"27","author":"E Sum","year":"2021","unstructured":"Sum, E. et al. Fibroblast activation protein \u03b1-targeted CD40 agonism abrogates systemic toxicity and enables administration of high doses to induce effective antitumor immunity. Clin. Cancer Res. 27, 4036\u20134053 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1157_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1158\/1535-7163.MCT-11-0340","volume":"11","author":"WN Brennen","year":"2012","unstructured":"Brennen, W. N., Isaacs, J. T. & Denmeade, S. R. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol. Cancer Ther. 11, 257\u2013266 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"1157_CR21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S0952-7915(97)80078-7","volume":"9","author":"CV Kooten","year":"1997","unstructured":"Kooten, C. V. & Banchereau, J. Functions of CD40 on B cells, dendritic cells and other cells. Curr. Opin. Immunol. 9, 330\u2013337 (1997).","journal-title":"Curr. Opin. Immunol."},{"key":"1157_CR22","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","volume":"4","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher, J. P. & Reis e Sousa, C. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer 4, 784\u2013792 (2018).","journal-title":"Trends Cancer"},{"key":"1157_CR23","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1084\/jem.192.12.1685","volume":"192","author":"JMM den Haan","year":"2000","unstructured":"den Haan, J. M. M., Lehar, S. M. & Bevan, M. J. CD8+ but not CD8\u2212 dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192, 1685\u20131696 (2000).","journal-title":"J. Exp. Med."},{"key":"1157_CR24","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.4049\/jimmunol.177.4.2265","volume":"177","author":"LB Arruda","year":"2006","unstructured":"Arruda, L. B. et al. Dendritic cell-lysosomal-associated membrane protein (LAMP) and LAMP-1-HIV-1 gag chimeras have distinct cellular trafficking pathways and prime T and B cell responses to a diverse repertoire of epitopes. J. Immunol. 177, 2265\u20132275 (2006).","journal-title":"J. Immunol."},{"key":"1157_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S1074-7613(00)80615-9","volume":"9","author":"B de Saint-Vis","year":"1998","unstructured":"de Saint-Vis, B. et al. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity. 9, 325\u2013336 (1998).","journal-title":"Immunity."},{"key":"1157_CR26","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1164206","volume":"322","author":"K Hildner","year":"2008","unstructured":"Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8\u03b1+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097\u20131100 (2008).","journal-title":"Science"},{"key":"1157_CR27","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1158\/0008-5472.CAN-22-1046","volume":"82","author":"A Teijeira","year":"2022","unstructured":"Teijeira, A. et al. Depletion of conventional type-1 dendritic cells in established tumors suppresses immunotherapy efficacy. Cancer Res. 82, 4373\u20134385 (2022).","journal-title":"Cancer Res."},{"key":"1157_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","volume":"6","author":"AR S\u00e1nchez-Paulete","year":"2016","unstructured":"S\u00e1nchez-Paulete, A. R. et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 6, 71\u201379 (2016).","journal-title":"Cancer Discov."},{"key":"1157_CR29","doi-asserted-by":"crossref","unstructured":"Ferris, S. T. et al. cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity. Nature 584, 624\u2013629 (2020).","DOI":"10.1038\/s41586-020-2611-3"},{"key":"1157_CR30","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00262-007-0286-3","volume":"56","author":"A Lad\u00e1nyi","year":"2007","unstructured":"Lad\u00e1nyi, A. et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol. Immunother. 56, 1459\u20131469 (2007).","journal-title":"Cancer Immunol. Immunother."},{"key":"1157_CR31","doi-asserted-by":"publisher","first-page":"E7759","DOI":"10.1073\/pnas.1609376113","volume":"113","author":"S Spranger","year":"2016","unstructured":"Spranger, S. et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc. Natl Acad. Sci. USA 113, E7759\u2013e7768 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1157_CR32","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.immuni.2023.08.009","volume":"56","author":"WH Fridman","year":"2023","unstructured":"Fridman, W. H. et al. Tertiary lymphoid structures and B cells: an intratumoral immunity cycle. Immunity 56, 2254\u20132269 (2023).","journal-title":"Immunity"},{"key":"1157_CR33","doi-asserted-by":"publisher","unstructured":"Mohr, P. et al. Advances and challenges in immunoPET methodology. Front. Nucl. Med. https:\/\/doi.org\/10.3389\/fnume.2024.1360710 (2024).","DOI":"10.3389\/fnume.2024.1360710"},{"key":"1157_CR34","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/ijc.32141","volume":"145","author":"SMM Irenaeus","year":"2019","unstructured":"Irenaeus, S. M. M. et al. First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies. Int. J. Cancer 145, 1189\u20131199 (2019).","journal-title":"Int. J. Cancer"},{"key":"1157_CR35","doi-asserted-by":"publisher","unstructured":"Luke, J. J. et al. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2020-002015 (2021).","DOI":"10.1136\/jitc-2020-002015"},{"key":"1157_CR36","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1158\/2326-6066.CIR-14-0182","volume":"3","author":"J Medina-Echeverz","year":"2015","unstructured":"Medina-Echeverz, J. et al. Systemic agonistic anti-CD40 treatment of tumor-bearing mice modulates hepatic myeloid-suppressive cells and causes immune-mediated liver damage. Cancer Immunol. Res. 3, 557\u2013566 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"1157_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi7083","volume":"6","author":"M Siwicki","year":"2021","unstructured":"Siwicki, M. et al. Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy. Sci. Immunol. 6, eabi7083 (2021).","journal-title":"Sci. Immunol."},{"key":"1157_CR38","doi-asserted-by":"publisher","first-page":"e000624","DOI":"10.1136\/jitc-2020-000624","volume":"8","author":"C Bonnans","year":"2020","unstructured":"Bonnans, C. et al. CD40 agonist-induced IL-12p40 potentiates hepatotoxicity. J. Immunother. Cancer 8, e000624 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1157_CR39","doi-asserted-by":"crossref","unstructured":"Young, L. S. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface fas ligand expression and amplifies fas-mediated hepatocyte death during allograft rejection. J. Exp. Med. 189, 441\u2013446 (1999).","DOI":"10.1084\/jem.189.2.441"},{"key":"1157_CR40","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","volume":"570","author":"AP Croft","year":"2019","unstructured":"Croft, A. P. et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570, 246\u2013251 (2019).","journal-title":"Nature"},{"key":"1157_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41413-022-00243-8","volume":"11","author":"A Fan","year":"2023","unstructured":"Fan, A. et al. Inhibition of fibroblast activation protein ameliorates cartilage matrix degradation and osteoarthritis progression. Bone Res. 11, 3 (2023).","journal-title":"Bone Res."},{"key":"1157_CR42","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1093\/eurheartj\/ehq519","volume":"32","author":"CE Brokopp","year":"2011","unstructured":"Brokopp, C. E. et al. Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata. Eur. Heart J. 32, 2713\u20132722 (2011).","journal-title":"Eur. Heart J."},{"key":"1157_CR43","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/metabo15040243","volume":"15","author":"A Mohmand-Borkowski","year":"2025","unstructured":"Mohmand-Borkowski, A. et al. Fibroblast activation protein compared with other markers of activated smooth muscle cells, extracellular matrix turnover and inflammation in a mouse model of atherosclerosis. Metabolites 15, 243 (2025).","journal-title":"Metabolites"},{"key":"1157_CR44","unstructured":"Scott, A. M. et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 9, 1639\u20131647 (2003)."},{"key":"1157_CR45","first-page":"44","volume":"26","author":"R-D Hofheinz","year":"2003","unstructured":"Hofheinz, R.-D. et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 26, 44\u201348 (2003).","journal-title":"Onkologie"},{"key":"1157_CR46","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng, S. et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 184, 792\u2013809 (2021).","journal-title":"Cell"},{"key":"1157_CR47","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1158\/0008-5472.CAN-03-2969","volume":"64","author":"M Movassagh","year":"2004","unstructured":"Movassagh, M. et al. Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res. 64, 2192\u20132198 (2004).","journal-title":"Cancer Res."},{"key":"1157_CR48","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1200\/JCO.2007.15.0284","volume":"26","author":"MC Dieu-Nosjean","year":"2008","unstructured":"Dieu-Nosjean, M. C. et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26, 4410\u20134417 (2008).","journal-title":"J. Clin. Oncol."},{"key":"1157_CR49","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1164\/rccm.201309-1611OC","volume":"189","author":"C Germain","year":"2014","unstructured":"Germain, C. et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am. J. Respir. Crit. Care Med. 189, 832\u2013844 (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1157_CR50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s40425-018-0446-3","volume":"6","author":"I Truxova","year":"2018","unstructured":"Truxova, I. et al. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J. Immunother. Cancer 6, 139 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"1157_CR51","doi-asserted-by":"publisher","unstructured":"Osorio, J. C. et al. Intratumoral Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity in patients with metastatic cancer. Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-4244833\/v1 (2024).","DOI":"10.21203\/rs.3.rs-4244833\/v1"},{"key":"1157_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24347-7","volume":"12","author":"L van Hooren","year":"2021","unstructured":"van Hooren, L. et al. Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma. Nat. Commun. 12, 4127 (2021).","journal-title":"Nat. Commun."},{"key":"1157_CR53","first-page":"S1535","volume":"25","author":"JC Osoria","year":"2025","unstructured":"Osoria, J. C. et al. Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell 25, S1535\u2013S6108 (2025).","journal-title":"Cancer Cell"},{"key":"1157_CR54","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow, A., Perica, K., Klebanoff, C. A. & Wolchok, J. D. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 19, 775\u2013790 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1157_CR55","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41590-024-01896-9","volume":"25","author":"CC Zebley","year":"2024","unstructured":"Zebley, C. C., Zehn, D., Gottschalk, S. & Chi, H. T cell dysfunction and therapeutic intervention in cancer. Nat. Immunol. 25, 1344\u20131354 (2024).","journal-title":"Nat. Immunol."},{"key":"1157_CR56","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1159\/000368006","volume":"32","author":"T Arizumi","year":"2014","unstructured":"Arizumi, T. et al. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Dig Dis. 32, 705\u2013710 (2014).","journal-title":"Dig Dis."},{"key":"1157_CR57","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1634\/theoncologist.2010-0064","volume":"16","author":"HW van Laarhoven","year":"2011","unstructured":"van Laarhoven, H. W. et al. When hope is all there is left. Oncologist 16, 914\u2013916 (2011).","journal-title":"Oncologist"},{"key":"1157_CR58","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1158\/1078-0432.CCR-20-4717","volume":"27","author":"S Labiano","year":"2021","unstructured":"Labiano, S. et al. CD40 agonist targeted to fibroblast activation protein \u03b1 synergizes with radiotherapy in murine HPV-positive head and neck tumors. Clin. Cancer Res. 27, 4054\u20134065 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1157_CR59","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/sim.3230","volume":"27","author":"B Neuenschwander","year":"2008","unstructured":"Neuenschwander, B., Branson, M. & Gsponer, T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat. Med. 27, 2420\u20132439 (2008).","journal-title":"Stat. Med."},{"key":"1157_CR60","doi-asserted-by":"crossref","unstructured":"Dejardin, D. et al. A composite decision rule of CD8+ T-cell density in tumor biopsies predicts efficacy in early-stage, immunotherapy trials. Clin. Cancer Res. 30, 877\u2013882 (2024).","DOI":"10.1158\/1078-0432.CCR-23-1572"},{"key":"1157_CR61","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nprot.2010.13","volume":"5","author":"MJ Vosjan","year":"2010","unstructured":"Vosjan, M. J. et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat. Protoc. 5, 739\u2013743 (2010).","journal-title":"Nat. Protoc."},{"key":"1157_CR62","doi-asserted-by":"crossref","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"1157_CR63","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1517\/17425250902992901","volume":"5","author":"L Gibiansky","year":"2009","unstructured":"Gibiansky, L. & Gibiansky, E. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin. Drug Metab. Toxicol. 5, 803\u2013812 (2009).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"1157_CR64","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/cyto.a.24334","volume":"99","author":"F Junker","year":"2021","unstructured":"Junker, F. et al. A human receptor occupancy assay to measure anti-PD-1 binding in patients with prior anti-PD-1. Cytometry A 99, 832\u2013843 (2021).","journal-title":"Cytometry A"},{"key":"1157_CR65","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.medj.2024.03.015","volume":"5","author":"R Schlenker","year":"2024","unstructured":"Schlenker, R. et al. Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma. Medicine 5, 759\u2013779 (2024).","journal-title":"Medicine"},{"key":"1157_CR66","unstructured":"FastQC v.0.11.9 (Babraham Bioinformatics, 2019)."},{"key":"1157_CR67","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"1157_CR68","doi-asserted-by":"crossref","unstructured":"Ewels, P., Magnusson, M., Lundin, S. & K\u00e4ller, M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics 32, 3047\u20133048 (2016).","DOI":"10.1093\/bioinformatics\/btw354"},{"key":"1157_CR69","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"1157_CR70","unstructured":"R v.4.2.0 (R Foundation for Statistical Computing, 2022)."},{"key":"1157_CR71","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47\u2013e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"1157_CR72","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"1157_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2014-15-2-r29","volume":"15","author":"CW Law","year":"2014","unstructured":"Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).","journal-title":"Genome Biol."},{"key":"1157_CR74","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1093\/nar\/gks461","volume":"40","author":"D Wu","year":"2012","unstructured":"Wu, D. & Smyth, G. K. Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res. 40, e133 (2012).","journal-title":"Nucleic Acids Res."},{"key":"1157_CR75","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"1157_CR76","doi-asserted-by":"crossref","unstructured":"Danaher, P. et al. Gene expression markers of tumor infiltrating leukocytes. J. Immunother. Cancer 5, 18 (2017).","DOI":"10.1186\/s40425-017-0215-8"},{"key":"1157_CR77","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2021.12.004","volume":"185","author":"AJ Combes","year":"2022","unstructured":"Combes, A. J. et al. Discovering dominant tumor immune archetypes in a pan-cancer census. Cell 185, 184\u2013203 (2022).","journal-title":"Cell"},{"key":"1157_CR78","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","volume":"579","author":"TD Wu","year":"2020","unstructured":"Wu, T. D. et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, 274 (2020).","journal-title":"Nature"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01157-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01157-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01157-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:02:06Z","timestamp":1780063326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01157-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":78,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["1157"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01157-8","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The following competing interests are declared. I.M.: Grants from F. Hoffmann-La Roche, AstraZeneca, BMS and Genmab; honoraria from Curon, Pharmamark, Pioneering Medicines, F. Hoffmann-La Roche, AstraZeneca, BMS, Genmab, Pierre Fabre, F-Star, Merus, Alligator Bioscience AB and Bright Peaks. B.R.: Employed at F. Hoffmann-La Roche; stock ownership at F. Hoffmann-La Roche. C.R.: Employed at F. Hoffmann-La Roche; stock ownership at F. Hoffmann-La Roche. A.E.: Employed at Roche Diagnostics Deutschland; stock ownership at F. Hoffmann-La Roche. N.A.K.: Employed at F. Hoffmann-La Roche. C.W.: Employed at Roche (China) Holding; stock ownership at F. Hoffmann-La Roche. M.H.: Employed at F. Hoffmann-La Roche; stock ownership at F. Hoffmann-La Roche. G.K.: Employed at F. Hoffmann-La Roche; stock ownership at F. Hoffmann-La Roche. N.R.: Employed at Roche Diagnostics GmbH Deutschland; stock ownership at F. Hoffmann-La Roche. P.C.S.: Employed at F. Hoffmann-La Roche; stock ownership at F. Hoffmann-La Roche. S.B.: Employed at F. Hoffmann-La Roche; stock ownership at F. Hoffmann-La Roche. N.K.: Employed at F. Hoffmann-La Roche; stock ownership at F. Hoffmann-La Roche. A.T.: Employed at F. Hoffmann-La Roche; stock ownership at F. Hoffmann-La Roche. D.J.V.: Employed at Amsterdam University Medical Center. V.M.: Employed at START; consultancy with AbbVie, F. Hoffmann-La Roche, Bayer, BMS, Janssen, Syneos, Affimed, AstraZeneca, Merck and Ellipses Pharma; principal investigator for AbbVie; institutional funding from AbbVie, Achilles, Adaptimmune, ADC Therapeutics, Ascendis Pharma, AstraZeneca, Bayer, BeiGene, Bicycle Tx, Bioinvent, Biomea Fusion, BioNTech SE, BMS, Boehringer Ingelheim, C4 Therapeutics, Calico Life Sciences LLC, Celgene, Constellation, Crescendo Biologics, Cullinan, Daiichi Sankyo, Debiopharm, Dragonfly, Enliven Therapeutics, Epizyme, Exelixis, FameWave, F-Star Beta Limited, Genentech, Genmab, Gilead, Grey Wolf Therapeutics, GSK, Hexal AG\/Sandoz, HiFiBiO, Hookipa Biotech, Hutchmed, IGM Biosciences, ImCheck Therapeutics, Immunocore, Immutep, Incyte, IOmx Therapeutics, Iovance, Italfarmaco, Iteos, Janssen, Light Chain Bioscience, Lilly, Loxo Oncology, Merck, Merus, Miltenyi Biomedicine, Monta Biosciences, MSD, Mythic Therapeutics, Ningbo Newbay, Novartis, Oxford BioTherapeutics, Pfizer, PharmaMar, PMV Pharma, Prelude Therapeutics Inc, Pyxis Oncology, Regeneron, Relay Therapeutics, Repare Therapeutics, Revolution, F. Hoffmann-La Roche, Schr\u00f6dinger, Scorpion Therapeutics, Seagen, Shattuck, Synthorx, Takeda, Tango Therapeutics, Tesaro, Totus Medicines, Turning Point Therapeutics and Vividion Therapeutics. J.L.B.: Consultancy with Daiichi Sankyo and Novartis. E.C.A.: Honoraria from GSK, Pfizer, Novartis, F. Hoffmann-La Roche, BMS, Gilead, PI Roche, BMS, AstraZeneca, EISAI, Italfarmaco, IO Biotech, Iovance and MSD. I.S.: Institutional research grants from F. Hoffmann-La Roche, AstraZeneca, Bayer, Boehringer Ingelheim, CDR-Life, Genentech, Incyte, MSD, Orion, Pfizer and Puma Biotechnology; honoraria from AstraZeneca; support for travel, accommodation and congress registration from AstraZeneca and Incyte. J.S.: Stock ownership at Epsilogen and co-founder of Avacta; board membership with Apobec, Discovery; reimbursement to their institution (for recruitment to clinical trials) from Achilles, Gilead, GSK, IO Biotech, MSD, F. Hoffmann-La Roche, RS Oncology and Starpharma; reimbursement to their institution for advisory roles from Apobec, Discovery, Avacta, AstraZeneca, BioNTech, BMS and F. Hoffmann-La Roche. F.T.: Speaker\/consultancy\/advisory with GSK, BMS, T-knife Therapeutics, Immatics, Scenic Biotec, F-Star, Kite, Leucid, CytomX, Grey Wolf and AstraZeneca; research income from GSK and Novartis. D-Y.O.: Research funding from AstraZeneca, Novartis, Array, Eli Lilly, Servier, BeiGene, MSD and Handon; advisory committees with AstraZeneca, Novartis, Genentech\/F. Hoffmann-La Roche, Merck Serono, Bayer, Taiho, ASLAN, Halozyme, Zymeworks, BMS\/Celgene, BeiGene, Basilea, Turning Point, Yuhan, Arcus Biosciences, IQVIA, MSD, LG Chem, Astellas, AbbVie, J-Pharma, Mirati Therapeutics, Eutilex, Moderna, Idience, Alligator Bioscience AB and Hana Pharm. A.H.: Consulting fees from Amgen, Sanofi, BMS, Basilea, Incyte, Servier, Relay Therapeutics, Taiho and MSD; honoraria from Incyte, Servier and Seagen; meeting attendance support from Pierre Fabre; participation on a data safety monitoring board or advisory Board for Basilea, QED Therapeutics, Taiho, Relay Therapeutics and MSD. O.C.: Employed at F. Hoffmann-La Roche.; stock ownership at F. Hoffmann-La Roche. S.N.S.: Research funding from MSD & Verastem; advisory committees for Duke St Bio, Ellipses, Exscientia, Grey Wolf Therapeutics, Medannex, MSD and F. Hoffmann-La Roche. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}